Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes
Per‐Henrik Groop(University of Helsinki), Maija Feodoroff(University of Helsinki), Johan Wadén(Helsinki University Hospital), Milla Rosengård‐Bärlund, Carol Forsblom(University of Helsinki), Markku Saraheimo(Helsinki University Hospital), Ville‐Petteri Mäkinen(Helsinki University Hospital), Daniel Gordin(Helsinki University Hospital), Lena M. Thorn(University of Helsinki), Nina Tolonen(University of Helsinki), Marja‐Riitta Taskinen(Hospital District of Helsinki and Uusimaa)
Cited by 78
Related Papers
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k